Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Gemcitabine and docetaxel (GEMDOX) for the treatment of relapsed and refractory pediatric sarcomas.

Rapkin L, Qayed M, Brill P, Martin M, Clark D, George BA, Olson TA, Wasilewski-Masker K, Alazraki A, Katzenstein HM.

Pediatr Blood Cancer. 2012 Nov;59(5):854-8. doi: 10.1002/pbc.24101. Epub 2012 Feb 2.

PMID:
22302783
2.

Treatment of relapsed/refractory pediatric sarcomas with gemcitabine and docetaxel.

Mora J, Cruz CO, Parareda A, de Torres C.

J Pediatr Hematol Oncol. 2009 Oct;31(10):723-9. doi: 10.1097/MPH.0b013e3181b2598c.

PMID:
19727011
3.

[Efficacy and safety of fixed dose rate gemcitabine infusion in combination with docetaxel in patients with relapsed/refractory soft tissue sarcoma].

Yao Z, Yang S, Zhao Y, Yao S, Guo H, Liu Y.

Zhonghua Zhong Liu Za Zhi. 2014 Jul;36(7):541-5. Chinese.

PMID:
25327662
4.

Efficacy and safety of gemcitabine-docetaxel combination therapy for recurrent or refractory high-grade osteosarcoma in China: a retrospective study of 18 patients.

Qi WX, He AN, Tang LN, Shen Z, Lin F, Yao Y.

Jpn J Clin Oncol. 2012 May;42(5):427-31. doi: 10.1093/jjco/hys030. Epub 2012 Mar 26.

PMID:
22450929
5.

Phase II study of weekly docetaxel and fixed dose rate gemcitabine in patients with previously treated advanced soft tissue and bone sarcoma.

Lee EM, Rha SY, Lee J, Park KH, Ahn JH.

Cancer Chemother Pharmacol. 2012 Mar;69(3):635-42. doi: 10.1007/s00280-011-1742-5. Epub 2011 Sep 30.

PMID:
21959979
6.

Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea Cancer Center Hospital experience.

Song BS, Seo J, Kim DH, Lim JS, Yoo JY, Lee JA.

Pediatr Blood Cancer. 2014 Aug;61(8):1376-81. doi: 10.1002/pbc.25035. Epub 2014 Apr 1.

PMID:
24692087
7.

Gemcitabine alone or combined with cisplatin in relapsed or refractory multiple myeloma.

Offidani M, Mele A, Corvatta L, Marconi M, Malerba L, Olivieri A, Rupoli S, Alesiani F, Leoni P.

Leuk Lymphoma. 2002 Jun;43(6):1273-9.

PMID:
12152996
8.

Docetaxel, bevacizumab, and gemcitabine for very high risk sarcomas in adolescents and young adults: A single-center experience.

Kuo C, Kent PM, Logan AD, Tamulonis KB, Dalton KL, Batus M, Fernandez K, Mcfall RE.

Pediatr Blood Cancer. 2017 Apr;64(4). doi: 10.1002/pbc.26265. Epub 2016 Nov 5.

PMID:
28221727
9.

Comparison of pirarubicin-based versus gemcitabine-docetaxel chemotherapy for relapsed and refractory osteosarcoma: a single institution experience.

He A, Qi W, Huang Y, Sun Y, Shen Z, Zhao H, Yang Y, Yao Y.

Int J Clin Oncol. 2013 Jun;18(3):498-505. doi: 10.1007/s10147-012-0409-5. Epub 2012 Apr 26.

PMID:
22534798
10.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
11.

Docetaxel and gemcitabine in the treatment of soft tissue sarcoma - a single-center experience.

Ebeling P, Eisele L, Schuett P, Bauer S, Schuette J, Moritz T, Seeber S, Flasshove M.

Onkologie. 2008 Feb;31(1-2):11-6. doi: 10.1159/0000111756. Epub 2008 Jan 22.

PMID:
18268394
12.

Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas.

Hingorani P, Eshun F, White-Collins A, Watanabe M.

J Pediatr Hematol Oncol. 2012 Oct;34(7):524-7.

PMID:
23007339
13.

Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].

Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, Fanucchi M, Harmon DC, Schuetze SM, Reinke D, Thall PF, Benjamin RS, Baker LH, Hensley ML.

J Clin Oncol. 2007 Jul 1;25(19):2755-63. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID:
17602081
14.

Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma.

Navid F, Willert JR, McCarville MB, Furman W, Watkins A, Roberts W, Daw NC.

Cancer. 2008 Jul 15;113(2):419-25. doi: 10.1002/cncr.23586.

15.

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.

Yoon JH, Kwon MM, Park HJ, Park SY, Lim KY, Joo J, Park BK.

BMC Cancer. 2014 Aug 28;14:622. doi: 10.1186/1471-2407-14-622.

16.

Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience.

Van Winkle P, Angiolillo A, Krailo M, Cheung YK, Anderson B, Davenport V, Reaman G, Cairo MS.

Pediatr Blood Cancer. 2005 Apr;44(4):338-47.

PMID:
15503297
17.

Update on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomas.

Hensley ML.

Curr Opin Oncol. 2010 Jul;22(4):356-61. doi: 10.1097/CCO.0b013e32833aafef. Review.

PMID:
20520541
18.

A phase II study of combination chemotherapy in early relapsed epithelial ovarian cancer using gemcitabine and pegylated liposomal doxorubicin.

Mirza MR, Lund B, Lindegaard JC, Keldsen N, Mellemgaard A, Christensen RD, Bertelsen K.

Gynecol Oncol. 2010 Oct;119(1):26-31. doi: 10.1016/j.ygyno.2010.06.022. Epub 2010 Jul 17.

PMID:
20638711
19.

Gemcitabine and docetaxel in relapsed and unresectable high-grade osteosarcoma and spindle cell sarcoma of bone.

Palmerini E, Jones RL, Marchesi E, Paioli A, Cesari M, Longhi A, Meazza C, Coccoli L, Fagioli F, Asaftei S, Grignani G, Tamburini A, Pollack SM, Picci P, Ferrari S.

BMC Cancer. 2016 Apr 20;16:280. doi: 10.1186/s12885-016-2312-3.

20.

Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies.

Mekhail T, Hutson TE, Elson P, Budd GT, Srkalovic G, Olencki T, Peereboom D, Pelley R, Bukowski RM.

Cancer. 2003 Jan 1;97(1):170-8.

Supplemental Content

Support Center